Cyclophosphamide
Cyclophosphamide (CAS 50-18-0) is a synthetic alkylating agent structurally related to nitrogen mustard compounds that acts as a DNA-crosslinking cytotoxic compound in proliferating cells and exhibits immunosuppressive activity in a variety of immune cell populations. In addition, cyclophosphamide is bioactivated in the liver to generate active metabolites that enhance its antitumor effects.
In preclinical and clinical studies, cyclophosphamide induces apoptosis and inhibits cell proliferation, showing significant cytotoxicity against a variety of human tumor cell lines and animal models. It also suppresses humoral and cellular immune responses by interfering with the function and survival of lymphocytes.
In pharmaceutical and clinical applications, cyclophosphamide is widely used to treat malignant tumors, including lymphomas, leukemia, multiple myeloma, breast cancer, and ovarian cancer, as well as in conditioning regimens for bone marrow transplantation. At the same time, by virtue of its potent immunomodulatory effects, cyclophosphamide is an established agent in the management of certain autoimmune diseases.
Cyclophosphamide is widely used to establish immunosuppression animal models; after administration it depletes immune cells and suppresses immune function, and is often used in combination with antigens for immunomodulatory research.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 261.09 |
| Cas No. | 50-18-0 |
| Formula | C7H15Cl2N2O2P |
| Synonyms | NSC 26271; Endoxan; Cytoxan; Neosar; Procytox; Revimmune; Cytophosphane |
| Solubility | ≥11.85 mg/mL in H2O with gentle warming and ultrasonic; ≥13.05 mg/mL in DMSO; ≥50.8 mg/mL in EtOH |
| Chemical Name | N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine |
| Canonical SMILES | O=P1(N(CCCl)CCCl)OCCCN1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
9L gliosarcoma cells retrovirally transduced with CYP2B6 |
|
Reaction Conditions |
1 mM cyclophosphamide for 48 h incubation |
|
Applications |
Cyclophosphamide was shown to cause tumor cell death by stimulating apoptosis, as evidenced by the induction of plasma membrane blebbing, DNA fragmentation, and cleavage of the caspase 3 and caspase 7 substrate poly(ADP-ribose) polymerase in drug-treated cells. |
| Animal experiment:[2] | |
|
Animal models |
Female C57BL/6 mice, 8 weeks of age |
|
Dosage form |
2 mg Injected intraperitoneally |
|
Applications |
Low-dose cyclophosphamide not only decreased the number of regulatory T cells (TREGs), but also led to decreased functionality of TREGs. Cyclophosphamide treatment enhanced apoptosis and decreased homeostatic proliferation of these cells. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Molecular Pharmacology, 2001, 60(6): 1268-1279. 2. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 2005, 105(7): 2862-2868. |
|
Quality Control & MSDS
- View current batch:
Chemical structure





















